Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 19/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.61 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.61 |
| ▸ | RPS6KA1 | Q15418 | 3/20 | 0.61 |
| ▸ | CDK2 | P24941 | 2/20 | 0.61 |
| ▸ | AKT1 | P31749 | 8/20 | 0.59 |
| ▸ | AKT2 | P31751 | 8/20 | 0.59 |
| ▸ | AKT3 | Q9Y243 | 8/20 | 0.59 |
| ▸ | PRKACA | P17612 | 2/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | MARK3 | P27448 | 1/20 | 0.55 |
| ▸ | GRK5 | P34947 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | CLK2 | P49760 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14050028 | 0.87 | RPS6KA5 (0.77) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4761218 | 0.85 | RPS6KA5 (0.74) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL14252546 | 0.83 | RPS6KA5 (0.71) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4717360 | 0.82 | RPS6KA5 (0.69) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4715073 | 0.81 | RPS6KA5 (0.71) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL17595570 | 0.81 | RPS6KA5 (0.71) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4715015 | 0.80 | RPS6KA5 (0.67) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4719616 | 0.80 | RPS6KA5 (0.67) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4718805 | 0.80 | RPS6KA5 (0.67) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 | |
| SCHEMBL4761707 | 0.80 | RPS6KA5 (0.69) | RPS6KA5ROCK1RPS6KB1DYRK1ARPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016038143-A1 | MICROBIOCIDAL 4-(IMIDAZO[4,5-C]PYRIDIN-2-YL)-1,2,5-OXADIAZOL-3- AMINE COMPOUNDS HAVING AN OXIME GROUP IN POSITION 7 | SYNGENTA PARTICIPATIONS AG (CH) | 2016-03-17 | — | — | WO | disclosed |
| EP-1689393-A4 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| US-20070161665-A1 | Cancer treatment method | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | LEE DENNIS | 2007-05-31 | — | — | US | disclosed |
| EP-1689393-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| EP-1682123-A1 | CANCER TREATMENT METHOD | SmithKline Beecham (Cork) Limited (IE) | 2006-07-26 | — | — | EP | disclosed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | disclosed |
| WO-2005046678-A1 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005037198-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | RPS6KA5 375/4885ROCK1 846/4885RPS6KB1 668/4885 |
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | RPS6KA5 156/4885ROCK1 478/4885RPS6KB1 99/4885 |
| US-20070161665-A1 | Cancer treatment method | ERBB2, EGFR, PIK3CA | RPS6KA5 82/4885ROCK1 1167/4885RPS6KB1 199/4885 |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | TNK2, CDC42BPB, CDC42BPA | RPS6KA5 117/4885ROCK1 4/4885RPS6KB1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.